Drug Interaction Report

Atogepant and Rifampin: Interaction Details

A pharmacist-reviewed analysis of the Atogepant and Rifampin interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Rifampin

Rifadin
+

Atogepant

Qulipta Qulipta®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Jul 11, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 157 documented Atogepant interactions, 152 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Altered atogepant exposure

Interaction Deep Dive

Coadministration of atogepant (a substrate of CYP3A4 and OATP) with a strong CYP3A4 inducer may significantly increase atogepant exposure, and reduced atogepant exposure may result with concomitant use of an OATP inhibitor. RifAMPin is a strong CYP3A4 inducer and an OATP inhibitor. In pharmacokinetic studies, a single dose of rifAMPin increased atogepant AUC by 2.85-fold and Cmax by 2.23-fold; however, steady-state rifAMPin coadministration with atogepant reduced atogepant AUC by 60% and Cmax by 30%. For episodic migraine, the recommended dosage of atogepant with concomitant use of a CYP3A4 inducer that is an OATP inhibitor is 10 or 30 mg once daily. For chronic migraine, avoid concomitant use of a CYP3A4 inducer that is an OATP inhibitor with atogepant1.

Why it happens (mechanism)

Induction of CYP3A4-mediated metabolism of atogepant; inhibition of OATP-mediated atogepant transport of atogepant

Literature reports

3 reports — tap to read

a) In a pharmacokinetic study, coadministration of atogepant with steady-state rifAMPin (a strong CYP3A4 inducer) reduced atogepant AUC by 60% and Cmax by 30% in healthy subjects 1.

b) In a pharmacokinetic study, coadministration of atogepant with a single dose of rifAMPin (a OATP inhibitor) increased atogepant AUC by 2.85-fold and Cmax by 2.23-fold in healthy subjects 1.

c) In a drug interaction study, repeated doses of encorafenib 450 mg once daily and binimetinib (inhibitor of OATP1B1 and OATP1B3) 45 mg twice daily with a single dose of rosuvastatin (a sensitive substrate of OATP1B1 and OATP1B3) increased rosuvastatin Cmax by 2.7-fold and AUC by 1.6-fold 2.

Common questions

Can I take Atogepant and Rifampin together?

Altered atogepant exposure Always confirm with your pharmacist or prescriber before making any change.

How serious is the Atogepant and Rifampin interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Atogepant or Rifampin need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: QULIPTA(R) oral tablets, atogepant oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2025. DailyMed
  2. Product Information: BRAFTOVI(R) oral capsules, encorafenib oral capsules. Array BioPharma Inc (per FDA), Boulder, CO, 2024. DailyMed
Was this write-up helpful?
Rifampin

Keep reading about Rifampin

All Rifampin interactions (176)
Also serious with: Aficamten Fostemsavir Doravirine Nifedipine
Atogepant

Keep reading about Atogepant

All Atogepant interactions (157) Atogepant drug information
Also serious with: Ensitrelvir Nafcillin Injection Voclosporin Vinblastine
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Rifampin + Activated Charcoal Apple Asarabacca Beer Grapefruit Siberian Cocklebur St. John's Wort Sweet Orange + 214 more
Atogepant + Activated Charcoal Grapefruit St. John's Wort Acacia Rigidula Adrafinil African Wild Potato American Elder Astaxanthin + 136 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.